1. Home
  2. LTBR vs ANTX Comparison

LTBR vs ANTX Comparison

Compare LTBR & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lightbridge Corporation

LTBR

Lightbridge Corporation

HOLD

Current Price

$5.08

Market Cap

198.7M

ML Signal

HOLD

Logo AN2 Therapeutics Inc.

ANTX

AN2 Therapeutics Inc.

BUY

Current Price

$3.63

Market Cap

172.9M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
LTBR
ANTX
Founded
1992
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.7M
172.9M
IPO Year
2015
2022

Fundamental Metrics

Financial Performance
Metric
LTBR
ANTX
Price
$5.08
$3.63
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $9.00
AVG Volume (30 Days)
★ 640.8K
304.7K
Earning Date
11-02-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 32.56
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.87
$1.00
52 Week High
$28.44
$7.19

Technical Indicators

Market Signals
Indicator
LTBR
ANTX
Relative Strength Index (RSI) 33.45 29.86
Support Level $4.87 $2.87
Resistance Level $7.04 $5.15
Average True Range (ATR) 0.34 0.35
MACD -0.03 -0.08
Stochastic Oscillator 8.75 14.65

Price Performance

Historical Comparison
LTBR
ANTX

About LTBR Lightbridge Corporation

Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, engaged in research and development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

Share on Social Networks: